R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 3/7/20

1 month ago By Josh Neil
  • Share on

  • Facebook
  • Linkedin
Proventa International Weekly News

Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials, and Bayer has settled claims over weedkiller Roundup’s cancerous effects for over $10 billion. 

GILEAD SETS REMDESIVIR PRICES as U.S. BUYS ENTIRE STOCK – Gilead has set remdesivir’s price at $2,340 for a five-day treatment, or $390 per vial. When the drug starts selling through normal distribution channels, the price will rise to $520 a vial. Though the drug has not yet been formally approved as a treatment for COVID-19, the United States has already bought up the world’s stock of the drug. This has left none for the rest of the world for at least three months. 

PFIZER/BIONTECH COVID VACCINE SHOWS PROMISE IN PHASE 1/2 TRIALS – Pfizer and BioNTech have announced the results of the phase 1/2 trials for their coronavirus vaccine BNT162b1. Though only trialled in a small group so far, the drug has shown efficacy in neutralising the virus

BAYER SETTLES ROUNDUP CLAIMS FOR $10 BILLION – Bayer has agreed to pay $10.9 billion in order to settle a lawsuit over Roundup, a weedkiller that allegedly causes cancer in users. The company is also paying $1.22 billion in two other cases, one pertaining to polychlorinated biphenyl in water. In 2019, the company paid over $2 billion to a couple who developed cancer after using the weedkiller. Bayer has appealed the new rulings. 

In other news:

Clinical Trials
Oxford may be best hope for Covid-19 vaccine in 2020
Ultragenyx receives second FDA approval in two weeks with metabolic disease drug
Keytruda approved for colorectal cancer use after one month of review

Manufacturing
Scottish company Symbiosis to manufacture AstraZeneca’s Covid-19 vaccine

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020.

More news

Weekly News Round-up – 17/7/20

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...

3 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 17/7/20

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...

3 weeks ago

Weekly News Round-up – 10/7/20

In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....

4 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 10/7/20

In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....

4 weeks ago

Clinical Trial Continuity and the Impact of COVID-19

Here's a second chance to catch the fascinating keynote panel discussion with IQVIA, Eli Lilly and Co., EMD Serono/Merck KGaA and Janssen. See how you can prepare for a post-Covid world and ensure your clinical trials are more patient-centric than...

4 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Clinical Trial Continuity and the Impact of COVID-19

Here's a second chance to catch the fascinating keynote panel discussion with IQVIA, Eli Lilly and Co., EMD Serono/Merck KGaA and Janssen. See how you can prepare for a post-Covid world and ensure your clinical trials are more patient-centric than...

4 weeks ago
Working With us

Interested?
Reserve your space